Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study
Abstract
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- Gutierrez, C.; Schiff, R. HER2: Biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 2011, 135, 55–62. [Google Scholar] [CrossRef]
- Wolff, A.C.; McShane, L.M.; Hammond, M.E.H.; Allison, K.H.; Fitzgibbons, P.; Press, M.F.; Harvey, B.E.; Mangu, P.B.; Bartlett, J.M.S.; Hanna, W.; et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch. Pathol. Lab. Med. 2018, 142, 1364–1382. [Google Scholar] [CrossRef] [PubMed]
- Rakha, E.A.; Pinder, S.E.; Bartlett, J.M.S.; Ibrahim, M.; Starczynski, J.; Carder, P.J.; Provenzano, E.; Hanby, A.; Hales, S.; Lee, A.H.S.; et al. Updated UK recommendations for HER2 assessment in breast cancer. J. Clin. Pathol. 2015, 68, 93–99. [Google Scholar] [CrossRef] [PubMed]
- Rüschoff, J.; Dietel, M.; Baretton, G.; Arbogast, S.; Walch, A.; Monges, G.; Chenard, M.P.; Penault-Llorca, F.; Nagelmeier, I.; Schlake, W.; et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010, 457, 299–307. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.Y.; Zheng, Z.X.; Sun, Y.; Bai, Y.H.; Shi, Y.F.; Zhou, L.X.; Yao, Y.F.; Wu, A.W.; Cao, D.F. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J. Gastrointest. Oncol. 2019, 11, 335–347. [Google Scholar] [CrossRef] [PubMed]
- Kim, E.K.; Kim, K.A.; Lee, C.Y.; Shim, H.S. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS ONE 2017, 12, e17128. [Google Scholar] [CrossRef]
- Beha, G.; Muscatello, L.V.; Brunetti, B.; Asproni, P.; Millanta, F.; Poli, A.; Benazzi, C.; Sarli, G. Molecular phenotype of primary mammary tumours and distant metastases in female dogs and cats. J. Comp. Pathol. 2014, 150, 194–197. [Google Scholar] [CrossRef]
- Millanta, F.; Impellizeri, J.; McSherry, L.; Rocchigiani, G.; Aurisicchio, L.; Lubas, G. Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma—A marker of malignancy and possible therapeutic target. Vet. Comp. Oncol. 2018, 16, 297–300. [Google Scholar] [CrossRef] [PubMed]
- Yoshimoto, S.; Kato, D.; Kamoto, S.; Yamamoto, K.; Tsuboi, M.; Shinada, M.; Ikeda, N.; Tanaka, Y.; Yoshitake, R.; Eto, S.; et al. Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma. J. Vet. Med. Sci. 2019, 81, 1034–1039. [Google Scholar] [CrossRef]
- Yoshimoto, S.; Kato, D.; Kamoto, S.; Yamamoto, K.; Tsuboi, M.; Shinada, M.; Ikeda, N.; Tanaka, Y.; Yoshitake, R.; Eto, S.; et al. Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer. J. Vet. Med. Sci. 2020. [Google Scholar] [CrossRef]
- Yoshimoto, S.; Kato, D.; Kamoto, S.; Yamamoto, K.; Tsuboi, M.; Shinada, M.; Ikeda, N.; Tanaka, Y.; Yoshitake, R.; Eto, S.; et al. Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma. Heliyon 2019, 5, e02004. [Google Scholar] [CrossRef] [PubMed]
- Campos, L.C.; Silva, J.O.; Santos, F.S.; Araújo, M.R.; Lavalle, G.E.; Ferreira, E.; Cassali, G.D. Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer. J. Vet. Diagn. Investig. 2015, 27, 531–535. [Google Scholar] [CrossRef]
- Nguyen, F.; Peña, L.; Ibisch, C.; Loussouarn, D.; Gama, A.; Rieder, N.; Belousov, A.; Campone, M.; Abadie, J. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: Natural history and prognostic factors. Breast Cancer Res. Treat. 2018, 167, 635–648. [Google Scholar] [CrossRef] [PubMed]
- Hsu, W.L.; Huang, H.M.; Liao, J.W.; Wong, M.L.; Chang, S.C. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Vet. J. 2009, 180, 116–123. [Google Scholar] [CrossRef] [PubMed]
- Seung, B.J.; Cho, S.H.; Kim, S.H.; Lim, H.Y.; Sur, J.H. Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: Comparison with immunohistochemistry analysis. PLoS ONE 2020, 15, e229031. [Google Scholar] [CrossRef] [PubMed]
- Ressel, L.; Puleio, R.; Loria, G.R.; Vannozzi, I.; Millanta, F.; Caracappa, S.; Poli, A. HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome. Res. Vet. Sci. 2013, 94, 299–305. [Google Scholar] [CrossRef]
- Peña, L.; Gama, A.; Goldschmidt, M.H.; Abadie, J.; Benazzi, C.; Castagnaro, M.; Díez, L.; Gärtner, F.; Hellmén, E.; Kiupel, M.; et al. Canine Mammary Tumors: A Review and Consensus of Standard Guidelines on Epithelial and Myoepithelial Phenotype Markers, HER2, and Hormone Receptor Assessment Using Immunohistochemistry. Vet. Pathol. 2014, 51, 127–145. [Google Scholar] [CrossRef]
- Singer, J.; Weichselbaumer, M.; Stockner, T.; Mechtcheriakova, D.; Sobanov, Y.; Bajna, E.; Wrba, F.; Horvat, R.; Thalhammer, J.G.; Willmann, M.; et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol. Immunol. 2012, 50, 200–209. [Google Scholar] [CrossRef]
- Tsuboi, M.; Sakai, K.; Maeda, S.; Chambers, J.K.; Yonezawa, T.; Matsuki, N.; Uchida, K.; Nakayama, H. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder. Vet. Pathol. 2019, 56, 369–376. [Google Scholar] [CrossRef]
- Bartley, A.N.; Washington, M.K.; Colasacco, C.; Ventura, C.B.; Ismaila, N.; Benson, A.B.; Carrato, A.; Gulley, M.L.; Jain, D.; Kakar, S.; et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 2017, 35, 446–464. [Google Scholar] [CrossRef]
- Terragni, R.; Casadei Gardini, A.; Sabattini, S.; Bettini, G.; Amadori, D.; Talamonti, C.; Vignoli, M.; Capelli, L.; Saunders, J.H.; Ricci, M.; et al. EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? PLoS ONE 2014, 9, e85388. [Google Scholar] [CrossRef] [PubMed]
- Hanken, H.; Gaudin, R.; Gröbe, A.; Fraederich, M.; Eichhorn, W.; Smeets, R.; Simon, R.; Sauter, G.; Grupp, K.; Izbicki, J.R.; et al. Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas. J. Oral Pathol. Med. 2014, 43, 304–308. [Google Scholar] [CrossRef]
- Birkeland, A.C.; Yanik, M.; Tillman, B.N.; Scott, M.V.; Foltin, S.K.; Mann, J.E.; Michmerhuizen, N.L.; Ludwig, M.L.; Sandelski, M.M.; Komarck, C.M.; et al. Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma. JAMA Otolaryngol. Head Neck Surg. 2016, 142, 559–567. [Google Scholar] [CrossRef] [PubMed]
- Sakai, K.; Maeda, S.; Saeki, K.; Yoshitake, R.; Goto-Koshino, Y.; Nakagawa, T.; Nishimura, R.; Yonezawa, T.; Matsuki, N. ErbB2 Copy Number Aberration in Canine Urothelial Carcinoma Detected by a Digital Polymerase Chain Reaction Assay. Vet. Pathol. 2020, 57, 56–65. [Google Scholar] [CrossRef] [PubMed]
- Seol, H.; Lee, H.J.; Choi, Y.; Lee, H.E.; Kim, Y.J.; Kim, J.H.; Kang, E.; Kim, S.W.; Park, S.Y. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: Its clinicopathological significance. Mod. Pathol. 2012, 25, 938–948. [Google Scholar] [CrossRef]
Tumor | n. Cases | 3+ (Positive) | 2+ (Equivocal) | 1+ (Negative) | 0 (Negative) |
---|---|---|---|---|---|
Intestinal | 15 | 12 (80%) | 2 (13.3%) | 1 (6.6%) | 0 |
Rectal | 14 | 6 (42.8%) | 5 (35.7%) | 1 (7.14%) | 2 (14.2%) |
cSCC | 14 | 4 (28.5%) | 2 (14.3%) | 2 (14.3%) | 6 (42.8%) |
oSCC | 8 | 3 (37.2%) | 1 (12.8%) | 3 (37.5%) | 1 (12.5%) |
Urothelial | 8 | 6 (75%) | 1 (12.5%) | 1 (12.5%) | 0 |
Ovarian | 7 | 2 (28.5%) | 2 (28.5%) | 2 (28.5%) | 1 (14.3%) |
Prostatic | 5 | 3 (60%) | 0 | 1 (20%) | 1 (20%) |
Pulmonary | 4 | 2 (50%) | 0 | 1 (25%) | 1 (25%) |
Renal | 4 | 2 (50%) | 0 | 0 | 2 (50%) |
Gastric | 3 | 1 (33.3%) | 1 (33.3%) | 0 | 1 (33.3%) |
Total | 82 | 41 | 14 | 12 | 15 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brunetti, B.; Bacci, B.; Sarli, G.; Pancioni, E.; Muscatello, L.V. Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study. Animals 2021, 11, 1006. https://doi.org/10.3390/ani11041006
Brunetti B, Bacci B, Sarli G, Pancioni E, Muscatello LV. Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study. Animals. 2021; 11(4):1006. https://doi.org/10.3390/ani11041006
Chicago/Turabian StyleBrunetti, Barbara, Barbara Bacci, Giuseppe Sarli, Elisa Pancioni, and Luisa Vera Muscatello. 2021. "Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study" Animals 11, no. 4: 1006. https://doi.org/10.3390/ani11041006
APA StyleBrunetti, B., Bacci, B., Sarli, G., Pancioni, E., & Muscatello, L. V. (2021). Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study. Animals, 11(4), 1006. https://doi.org/10.3390/ani11041006